# A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants

> **NCT05877222** · PHASE1 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 38 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Daridorexant 10 mg
- **DRUG:** Daridorexant 25 mg

## Key facts

- **NCT ID:** NCT05877222
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-23
- **Primary completion:** 2023-08-04
- **Final completion:** 2023-08-04
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2023-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05877222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05877222, "A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05877222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*